Search for a trial

An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution.

A new formulation of DuoTrav® eye drops, called DuoTrav APS, in which, the preservative (BAC) has been replaced by a new preservative called POLYQUAD has been developed. POLYQUAD is expected to be better tolerated in the eye, especially for the…

A randomized, open-label, comparative trial to evaluate the effects on ovarian function of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estradiol (E2), compared to a monophasic COC containing 3 mg drospirenone (DRSP) and 30 µg ethinyl estradiol (EE).

To evaluate the effects on ovarian function with the NOMAC/E2 COC in a group of women aged 18-35 years.

A randomized, open-label, comparative, multi-center trial to evaluate contraceptive efficacy, cycle control, safety and acceptability of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estradiol (E2), compared to a monophasic COC containing 3 mg drospirenone (DRSP) and 30 ug ethinyl estradiol (EE).

• To assess contraceptive efficacy, vaginal bleeding patterns (cycle control),general safety and acceptability of the NOMAC-E2 COC in a large group ofwomen aged 18-50 years.

A Phase 1, Open-label, Single-dose, Randomized, Crossover Study to Assess the Local Tolerability of the Tildrakizumab 200 mg Dose when Delivered as Single Subcutaneous Injection via the 200 mg/2 mL Pre-filled Syringe

The purpose of this study is to investigate how well a new dosage form of tildrakizumab is tolerated when it is administered to healthy volunteers. Tildrakizumab (also known as Ilumetri) is no new compound; it is already available on the market as a…

Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio study

The primary goal is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care. This is measured by comparing the proportion of long-term disease flares between the two groups (dose…

An open-label, randomised, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy.

Primary objectiveTo assess the efficacy of tildrakizumab treatment (as assessed by PASI 75) in moderate-to-severe plaque psoriasis patients who are non-responders to DMF. Secondary objectivesTildrakizumab- To assess the efficacy of tildrakizumab…